Akio Aono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akio Aono has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Mitarai
The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
23 shared publications - Hiroyuki Yamada
Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
8 shared publications Kinuyo Chikamatsu
Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association , 3-1-24 Matsuyama, Kiyose, Tokyo 204-8533
7 shared publications- Kinuyo Chikamatsu
Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
7 shared publications Akiko Takaki
Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
5 shared publicationsHiroyuki Yamada
Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
5 shared publications
Latest Publications
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis : a proof-of-concept study
Objectives: To evaluate MPT64 secretion as a viability-associated readout for rapid phenotypic drug susceptibility testing (pDST) of Mycobacterium tuberculosis. Methods: We evaluated MPT64-pDST in 130 M. tuberculosis strains: clinical isolates, WHO quality assessment strains and in vitro-selected resistant mutants (for linezolid only). We assessed the diagnostic performance of MPT64-pDST for determining susceptibility to rifampicin, isoniazid and moxifloxacin. As a secondary objective, we explored its performance for linezolid and bedaquiline. MPT64 was quantified by chemiluminescent enzyme immunoassay, and susceptibility was inferred from Log2 fold change relative to drug-free controls. Reference standards were minimum inhibitory concentration testing for rifampicin, isoniazid, linezolid and bedaquiline and MGIT-based DST for moxifloxacin. Performance was evaluated using receiver operating characteristic analysis, full-dataset Youden-optimal candidate cutoffs and 2000-iteration stratified bootstrap out-of-bag (OOB) internal validation. Results: Using drug-specific full-dataset Youden-optimal candidate cutoffs, MPT64-pDST showed high categorical agreement with reference DST, with no false-resistant classifications for rifampicin, isoniazid or moxifloxacin. Resistance-detection sensitivity was 100% for rifampicin, 98% for isoniazid and 90% for moxifloxacin, and out-of-bag bootstrap estimates were comparable to the full-dataset estimates. Exploratory analyses for linezolid demonstrated separation between susceptible and resistant mutants. The single bedaquiline-resistant isolate was clearly distinguishable from 39 bedaquiline-susceptible isolates. Conclusions: These findings provide proof of concept that the immunoassay-based MPT64-pDST can enable rapid phenotypic susceptibility classification for rifampicin, isoniazid and moxifloxacin. Further validation in larger isolate collections, including isolates with borderline phenotypes, is warranted.
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis : a proof-of-concept study
Objectives: To evaluate MPT64 secretion as a viability-associated readout for rapid phenotypic drug susceptibility testing (pDST) of Mycobacterium tuberculosis. Methods: We evaluated MPT64-pDST in 130 M. tuberculosis strains: clinical isolates, WHO quality assessment strains and in vitro-selected resistant mutants (for linezolid only). We assessed the diagnostic performance of MPT64-pDST for determining susceptibility to rifampicin, isoniazid and moxifloxacin. As a secondary objective, we explored its performance for linezolid and bedaquiline. MPT64 was quantified by chemiluminescent enzyme immunoassay, and susceptibility was inferred from Log2 fold change relative to drug-free controls. Reference standards were minimum inhibitory concentration testing for rifampicin, isoniazid, linezolid and bedaquiline and MGIT-based DST for moxifloxacin. Performance was evaluated using receiver operating characteristic analysis, full-dataset Youden-optimal candidate cutoffs and 2000-iteration stratified bootstrap out-of-bag (OOB) internal validation. Results: Using drug-specific full-dataset Youden-optimal candidate cutoffs, MPT64-pDST showed high categorical agreement with reference DST, with no false-resistant classifications for rifampicin, isoniazid or moxifloxacin. Resistance-detection sensitivity was 100% for rifampicin, 98% for isoniazid and 90% for moxifloxacin, and out-of-bag bootstrap estimates were comparable to the full-dataset estimates. Exploratory analyses for linezolid demonstrated separation between susceptible and resistant mutants. The single bedaquiline-resistant isolate was clearly distinguishable from 39 bedaquiline-susceptible isolates. Conclusions: These findings provide proof of concept that the immunoassay-based MPT64-pDST can enable rapid phenotypic susceptibility classification for rifampicin, isoniazid and moxifloxacin. Further validation in larger isolate collections, including isolates with borderline phenotypes, is warranted.
- Open Access
- 27 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9)
Concentration-dependent suppression of macrolide resistance in Mycobacterium avium by combination therapy: An improved in vitro time-kill assay and alveolar macrophage exposure-based pharmacokinetic/pharmacodynamic modeling study
- 27 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9)
Open AccessConcentration-dependent suppression of macrolide resistance in Mycobacterium avium by combination therapy: An improved in vitro time-kill assay and alveolar macrophage exposure-based pharmacokinetic/pharmacodynamic modeling study
- 17 June 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 231, 107718
Clofazimine serum concentration and safety/efficacy in nontuberculous mycobacterial pulmonary disease treatment
- 17 June 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 231, 107718
Clofazimine serum concentration and safety/efficacy in nontuberculous mycobacterial pulmonary disease treatment
- 15 June 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (6) , e0157922
In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus
The clinical importance of Mycobacterium abscessus species (MABS) infections has been increasing. However, the standard treatment regimens recommended in the current guidelines often result in unfavorable outcomes.
- 15 June 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (6) , e0157922
In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus
The clinical importance of Mycobacterium abscessus species (MABS) infections has been increasing. However, the standard treatment regimens recommended in the current guidelines often result in unfavorable outcomes.
- Open Access
- 15 June 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (3) , e0516222
Diagnostic Utility of a Mycobacterium Multiplex PCR Detection Panel for Tuberculosis and Nontuberculous Mycobacterial Infections
Species identification is important for the diagnosis of mycobacterial infections and decisions on treatment regimens. The Myco-Panel test accurately detects clinically common mycobacterial species that cause respiratory infections from clinical respiratory samples and mycobacterial suspensions.
- 15 June 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (3) , e0516222
Open AccessDiagnostic Utility of a Mycobacterium Multiplex PCR Detection Panel for Tuberculosis and Nontuberculous Mycobacterial Infections
Species identification is important for the diagnosis of mycobacterial infections and decisions on treatment regimens. The Myco-Panel test accurately detects clinically common mycobacterial species that cause respiratory infections from clinical respiratory samples and mycobacterial suspensions.
- Open Access
- 16 February 2023
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 12 (2) , e0121422
Complete Genome Sequences of 14 Nontuberculous Mycobacteria Type Strains
Here, we present the complete genome sequences of 14 nontuberculous mycobacteria type strains. The addition of type strain data may provide a concrete basis for further research.
- 16 February 2023
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 12 (2) , e0121422
Open AccessComplete Genome Sequences of 14 Nontuberculous Mycobacteria Type Strains
Here, we present the complete genome sequences of 14 nontuberculous mycobacteria type strains. The addition of type strain data may provide a concrete basis for further research.
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S63-S66
A Systemic Lupus Erythematosus Patient with Cutaneous Mycobacterium haemophilum Infection under Belimumab Treatment: A Case Report
Kim J, et al. Ann Dermatol. 2023 May;35:e45. https://doi.org/10.5021/ad.21.077
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S63-S66
Open AccessA Systemic Lupus Erythematosus Patient with Cutaneous Mycobacterium haemophilum Infection under Belimumab Treatment: A Case Report
Kim J, et al. Ann Dermatol. 2023 May;35:e45. https://doi.org/10.5021/ad.21.077
- Open Access
- 29 June 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (3) , e0009722
Potential Cross-Transmission of Mycobacterium abscessus among Non-Cystic Fibrosis Patients at a Tertiary Hospital in Japan
IMPORTANCE Although the possibility of Mycobacterium abscessus ( M. abscessus ) cross-transmission in cystic fibrosis (CF) patients has often been reported, it is not clear whether similar events have occurred in Asian non-CF patients. Whole-genome sequencing analysis of M. abscessus isolates from Fukujuji Hospital in Japan indicated that genetically closely related M. abscessus isolates exist.
- 29 June 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (3) , e0009722
Open AccessPotential Cross-Transmission of Mycobacterium abscessus among Non-Cystic Fibrosis Patients at a Tertiary Hospital in Japan
IMPORTANCE Although the possibility of Mycobacterium abscessus ( M. abscessus ) cross-transmission in cystic fibrosis (CF) patients has often been reported, it is not clear whether similar events have occurred in Asian non-CF patients. Whole-genome sequencing analysis of M. abscessus isolates from Fukujuji Hospital in Japan indicated that genetically closely related M. abscessus isolates exist.
- Open Access
- 21 March 2022
- Published by Elsevier in Tuberculosis
- Vol. 134, 102199
Clinical evaluation of the cobas® MTB-RIF/INH reagent and the cobas® 6800 for the detection of isoniazid and rifampicin resistance
- 21 March 2022
- Published by Elsevier in Tuberculosis
- Vol. 134, 102199
Open AccessClinical evaluation of the cobas® MTB-RIF/INH reagent and the cobas® 6800 for the detection of isoniazid and rifampicin resistance